SCHEMBL17824287

SCHEMBL17824287

Cn1nnnc1NC(=O)Cn1c(NCc2ccccc2)nc2ccccc21

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 5/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ TSHR P16473 1/20 0.51
▸ HTT P42858 1/20 0.51
▸ RAB9A P51151 2/20 0.51
▸ MEN1 O00255 1/20 0.51
▸ PKM P14618 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ USP2 O75604 1/20 0.48
▸ CYP1A2 P05177 2/20 0.48
▸ CYP2C19 P33261 2/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ CYP2D6 P10635 1/20 0.48
▸ ALDH1A1 P00352 3/20 0.47
▸ MAPT P10636 1/20 0.47
▸ CYP2C9 P11712 1/20 0.47
▸ OPRK1 P41145 1/20 0.46
▸ KDR P35968 1/20 0.46
▸ MCHR1 Q99705 1/20 0.46
▸ GSK3B P49841 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17824300 0.82 LMNA (0.50) LMNASMN1; SMN2TSHRHTTRAB9A
SCHEMBL17824301 0.81 LMNA (0.51) LMNASMN1; SMN2TSHRHTTRAB9A
SCHEMBL17824274 0.80 LMNA (0.53) LMNASMN1; SMN2TSHRHTTRAB9A
SCHEMBL19714478 0.80 LMNA (0.74) LMNASMN1; SMN2TSHRHTTRAB9A
SCHEMBL19714466 0.80 KMT2A (0.65) LMNASMN1; SMN2TSHRHTTRAB9A
SCHEMBL19714100 0.80 LMNA (0.73) LMNASMN1; SMN2TSHRHTTRAB9A
SCHEMBL17824304 0.79 LMNA (0.51) LMNASMN1; SMN2TSHRHTTRAB9A
SCHEMBL17824272 0.78 LMNA (0.53) LMNASMN1; SMN2TSHRHTTRAB9A
SCHEMBL17824291 0.78 LMNA (0.50) LMNASMN1; SMN2TSHRHTTRAB9A
SCHEMBL19728296 0.78 LMNA (0.50) LMNASMN1; SMN2TSHRHTTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170362184-A1 PRO-SURVIVAL COMPOUNDS HERIOT-WATT UNIVERSITY (GB) 2017-12-21 — — US disclosed
EP-3230275-A1 PRO-SURVIVAL COMPOUNDS University Court of The University of Glasgow (GB) 2017-10-18 — — EP disclosed
WO-2016092327-A1 PRO-SURVIVAL COMPOUNDS UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) 2016-06-16 — — WO disclosed
WO-2016092327-A1 PRO-SURVIVAL COMPOUNDS UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW (GB) 2016-06-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170362184-A1 PRO-SURVIVAL COMPOUNDS MCL1, MKI67, MORF4L1 LMNA 301/4885SMN1; SMN2 10/4885TSHR 4613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback